- MACD is crossing MACD signal line at 1.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Jim Cramer shares insights about buying General Electric, Arcturus vaccine, and Roblox filing to go public.
Messenger RNA (mRNA) coronavirus vaccine candidates now appear to be batting two for two. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced great interim efficacy results for their experimental mRNA COVID-19 vaccine last week. Are there other biotech stocks with mRNA vaccine programs that could also be winners?
Promising vaccine news lifted both companies’ stocks on hopes it will validate mRNA technology and speed other products to market.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) just released its latest third-quarter report and things are not...
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. Investors were less interested in Arcturus' financial results than they were in the company's encouraging interim phase 1/2 results for its coronavirus vaccine candidate ARCT-021. There's no question that ARCT-021 looked promising based on the company's interim phase 1/2 results.
The pharmaceutical giant’s good news could be good news for other vaccine makers who are far along in the testing process.
U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials showed promising results. Arcturus said its ARCT-021 vaccine candidate has been generally well tolerated in trials so far, with the majority of adverse events being mild.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?